<DOC>
	<DOCNO>NCT01342484</DOCNO>
	<brief_summary>The main objective study identify dose linagliptin paediatric patient . Other efficacy objective include comparison lower effect linagliptin low dose , high dose placebo fast plasma glucose ( FPG ) observe 12 wk treatment . Furthermore , study investigate pharmacokinetics ( PK ) , pharmacodynamics ( PD ) PK/PD relationship linagliptin paediatric population .</brief_summary>
	<brief_title>Finding Safe Effective Dose Linagliptin Pediatric Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Paediatric patient ( child adolescent ) , age 10 17 year document diagnosis type 2 diabetes mellitus 2 . Insufficient glycaemic control ( i.e . HbA1c &gt; 6.5 % &lt; = 10.5 % ) despite treatment diet exercise and/or metformin ( &gt; = 1000 mg per day ( maximum tolerate dose ) stable dose dose frequency 8 week prior randomisation ) and/or concomitant stable basal insulin ( total daily dose must &lt; = 0.5U/kg less 10 % weekly dose change 12 week prior randomisation ) 3 . Negative islet cell antigen ( ICA ) autoantibodies glutamic acid decarboxylase ( GAD ) autoantibodies 4 . Cpeptide level ( serum ) &gt; = 1.5 ng/ml ( 90 min follow Boost challenge ) Exclusion criterion : 1 . History acute metabolic decompensation , diabetic ketoacidosis , within 3 month 2 . Current shortacting insulin receive shortacting insulin 3 day within 1 month prior randomisation 3 . Treatment weight reduction medication ( include antiobesity treatment )</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>